Aehr Test Systems (AEHR) Q2 2026 earnings review
A massive 'Hockey Stick' bet: Weak Q2 results vs. Explosive H2 Promises
Aehr delivered a soft Q2 with revenue declining 27% YoY and margins collapsing to ~26% (GAAP) as the company swung to a loss. However, the narrative is entirely focused on a massive projected inflection point. Management reinstated guidance, forecasting H2 bookings of $60-80M—a 700%+ increase over H1 levels—driven by AI processor burn-in demand. Investors are effectively being asked to ignore the current poor financials and trust a near-vertical ramp in orders starting immediately.
🐂 Bull Case
The pivot from EV/Silicon Carbide to AI is showing tangible signs. A 'lead AI customer' is scaling, requesting additional capacity and transitioning to fully integrated automated WaferPaks. Management claims the $60-80M bookings forecast is based on 'customer forecasts recently provided,' suggesting high visibility.
Despite the net loss, cash and equivalents rose to $31.0M (up from $24.7M in Q1). The company has sufficient runway to weather the current lull before the anticipated revenue ramp in FY27.
🐻 Bear Case
The company needs to secure ~$70M in bookings in six months after securing only ~$8M in the last six. Any delay in customer timelines—common in semiconductor qualification—will cause a massive miss against reinstated guidance.
GAAP gross margin compressed to ~25.7% in Q2 from ~51% a year ago due to low volume absorption. If the volume ramp is delayed, the company will continue to bleed cash and report losses.
⚖️ Verdict: ⚪
Neutral/Speculative. The financials are currently poor (Reversing), but the guidance signals a massive pivot (Accelerating). This is no longer an earnings story; it is a binary event trade on whether the promised AI orders materialize in the next 3-6 months.
Key Themes
The $60-80M Bookings Inflection
Management forecasted H2 bookings between $60M and $80M. For context, Aehr booked only $6.2M in Q2 and implies ~$2M in Q1. This projection signals an unprecedented acceleration. If achieved, it validates the entire 'AI pivot' thesis and sets up FY27 for record revenues. If missed, credibility will be severely damaged.
AI Processor Demand (WLBI & PPBI)
The company is successfully diversifying away from Silicon Carbide. Growth is driven by a 'lead customer' for AI processors using Wafer-Level Burn-In (WLBI) and multiple customers for Packaged-Part Burn-In (PPBI/Sonoma). New orders of $5.5M for Sonoma systems in Q3-to-date already exceed total Q2 orders, validating some immediate momentum.
Profitability & Margin Compression
Margins have deteriorated significantly. GAAP Gross Margin fell to ~25.7% in Q2 (derived from $2.54M profit on $9.88M revenue) compared to 50%+ in prior years. The company posted a GAAP Net Loss of $3.2M. The business model has high fixed costs; without the promised volume surge, profitability will remain elusive.
Silicon Photonics & Memory
While AI is the headline, Aehr is planting seeds in Silicon Photonics (data center interconnects) and Flash Memory. Management notes a lead customer in silicon photonics is firming up production ramps for early next fiscal year. These serve as secondary call options if the AI ramp hits a snag.
Lack of Q2 Execution
Despite the rosy outlook, Q2 revenue was 'softer than anticipated' at $9.9M vs $13.5M YoY. This indicates that despite high engagement, closing deals and recognizing revenue remains lumpy and difficult to predict. The divergence between 'customer forecasts' and 'signed purchase orders' remains a key risk.
Other KPIs
Decelerating. Down 27% YoY and down ~10% sequentially from Q1 ($11.0M). The company is currently in a revenue trough between the decline of legacy SiC orders and the ramp of new AI orders.
Stable/Low. While effective backlog is cited as $18.3M (including bookings after quarter close), the base backlog remains thin relative to the $25-30M revenue guidance for H2, necessitating immediate book-and-ship execution.
Stable. Increased from $24.7M in August, largely due to financing activities (stock issuance mentioned in cash flow statement: +$9.6M YTD financing cash flow). Operating cash flow was negative $-1.5M for the first six months.
Guidance
Accelerating. Implies quarterly average of ~$12.5-15M, a step up from the ~$10M run rate in H1. This guidance assumes the 'softer' Q2 trends reverse immediately.
Accelerating significantly. This is the critical metric. It implies a massive wave of orders is imminent. If hit, it validates the FY27 growth story. If missed, the thesis breaks.
Stable/Negative. Even with the revenue ramp to $25-30M, the company expects to remain unprofitable on a net basis for the remainder of the fiscal year, suggesting margins will not fully recover until FY27 volumes kick in.
Key Questions
Bookings Confidence
You are guiding for $60-80M in bookings for H2 after doing only ~$8M in H1. How much of this H2 forecast is backed by firm commitments versus non-binding customer forecasts?
Margin Recovery Slope
Gross margins dipped to ~26% in Q2. At the guided revenue levels of $12.5-15M per quarter in H2, where do you expect gross margins to settle, and what is the breakeven revenue run rate now?
Cash Burn vs Ramp
With negative operating cash flow in H1 and projected net losses in H2, do you have sufficient working capital to fund the inventory build required for a $60M+ bookings ramp without raising further equity?
Silicon Carbide Status
Is the SiC business effectively zero in your H2 guidance, or are you baking in a recovery there alongside the AI growth?